People In Business United Kingdom 1

UK

UDG Healthcare chairman Peter Gray buys 20 September 2018

NEWS BITES - PEOPLE IN BUSINESS

UDG Healthcare (L:UDG) Chairman Peter Gray bought 14,000 shares worth GBP88,340 ($US116,154) on September 19. The purchase price was GBP6.31.

SECTION 1 PETER GRAY REPORTED BUYING IN 2018

+ In 2018 a total of 14,000 shares worth GBX8.8 million were bought. The highest number of shares 14,000 worth GBX8.8 million were bought in the month of September.

MonthNo. of SharesPrice, GBXValue, GBX
September 20, 201814,000631.08,834,000September

Source: London Stock Exchange

SECTION 2 BIOGRAPHY PETER GRAY, CHAIRMAN

Peter Gray (61) is Chairman and non-executive director of UDG Healthcare. Peter was appointed Chairman on 7 February 2012, having served as a non-executive director since 28 September 2004. Peter formerly held senior executive positions in a number of Irish public companies, most recently that of Vice Chairman and Chief Executive of ICON plc, the multinational pharmaceutical development services company. Peter is currently also a non-executive director of Jazz Pharmaceuticals plc, and two other private companies.

PermID: 34413224481

SECTION 3 UDG HEALTHCARE PLC PRICE PERFORMANCE SCORECARD (United Kingdom:UDG):

3.1 UDG Healthcare PLC is placed 1,090/1,343 in the BSS News Bites ranking of price performance of the United Kingdom stocks in the past year, a percentile ranking of 19.

3.2 Year-to-date

UDG Healthcare plummets 25% in 2018

UDG Healthcare PLC (L:UDG), plummeted GBX212.93 (or 25.2%) year-to-date (YTD) in 2018 to close at GBX630.50 today. Compared with the FTSE 100 Index which has fallen 3.8% YTD, this is a relative price change of -21.4%.

3.3 MCap History:

MCap: 5-Year Perspective

In the past 5 years Market Capitalization has increased by GBP765.5 million from GBP801.9 million to GBP1.6 billion. Based on a dynamic start date of 5 years ago, there have been declines in MCap in 2 out of 5 years.

PriceMCap (GBP M)MCap (US$ M)
LastGBX630.501,567.42,061.5
1 Year agoGBX841.942,116.42,854.4
2 Years agoGBX614.111,5412,035.6
3 Years agoGBX518.631,3202,047.4
4 Years agoGBX321.91816.91,331.6
5 Years agoGBX308.20801.91,275

3.4 Moving Annual Return (Past 5 years)

Based on a dynamic start date of 5 years ago, the Moving Annual Return has been positive in 4 out of 5 years.

UDGClose (GBX)Dividends (GBX)Capital Gain / (Loss) %% YieldAnnual Return %
Sep 19630.510.39(25.1)1.2(23.9)
1 Yr ago841.9410.1437.11.738.8
2 Yrs ago614.118.0418.41.520.0
3 Yrs ago518.637.9761.12.563.6
4 Yrs ago321.917.854.42.57.0

Close 5 years ago GBX308.20

3.5 Present Value of GBP1000 invested in the past

The present value of GBX1000 invested a year ago is GBX758

PV10001-week1-month1-year
UDG.L942812758
FTSE 100 Index1,0029621,008

3.6 Trailing Price Change %

1-Year price change for UDG Healthcare was -19.8%. Compared with the FTSE 100 Index which rose 1.1% in the year, the relative price change was -20.9%.

Price Change %1-Month3-Month1-Year
UDG-14.7-21.8-19.8
Food & drug retailers sector-6.7-4.6-30.5
FTSE 100 Index-3.1-3.61.1

SECTION 4 UDG HEALTHCARE PLC FINANCIALS AND GROWTH PERFORMANCE SCORECARD (United Kingdom:UDG):

4.1 Key Financials (All figures percent)

Return on Equity deteriorated from 18.3% in 2014 to 8.2% in 2017 and Operating Margin deteriorated from 23.8% in 2014 to 10.0% in 2017.

UDGRevenue GrowthEPS GrowthOperating MarginROE
201713.7-67.3108.2
201654.5-9.58.4
2015--14.46.9
2014--23.818.3

4.3 Performance (All figures in %)

Net Profit Margin 10-year average is 4.3% and Return on Assets 10-year average is 4.3%.

DescriptionAnnual10-year Avg
EBITDA Margin10.09.4
Operating Profit Margin10.07.9
Net Profit Margin5.94.3
Return on Equity8.210.6
Return on Assets4.74.3
Return on Capital Employed9.810.5

4.4 High Performance Indicator and rank of UDG Healthcare in the United Kingdom market:

DescriptionUDG ValueRank In United Kingdom Market
Turnover in QuarterGBP417.4 million (US$549 million)In Top 7%

SECTION 5 UDG HEALTHCARE PLC GLOBAL RANK (United Kingdom:UDG):

5.1 Global Rank

Global Rank [out of 47,639 stocks]

DescriptionValueRankQuartile
MCap (US$)2.1B5,009Top
Total Assets (US$)2B6,978Top
Revenue (US$)1.6B5,025Top
Net Profit (US$)94.5M5,655Top
Return on Equity %8.216,667Second
Net Profit Margin %5.916,892Second
Price to Book14.434,424Third
Price Earnings22.013,480Second
Yield %1.615,569Second
PV$1000 (1Year) US$*73428,315Third
US$* Change (1Year) %-26.628,309Third
Rel Strength 6 Mo (US$)3132,799Third

* 1 year ago GBP 1 = USD 1.35

Sep 19, 2018: GBP 1 equals USD 1.3152

SECTION 6 OTHER DIRECTORS OF UDG HEALTHCARE PLC

Brendan McAtamney, Chief Executive Officer

Peter Gray, Chairman

Nigel Clerkin, Chief Financial Officer & Executive Director

Alan Ralph, Managing Director

Philip Toomey, Non-Executive Director

Inda Wilding, Non-Executive Director

Myles Lee, Non-Executive Director

Nancy Miller-Rich, Non-Executive Director

Lisa Ricciardi, Non-Executive Director

Chris Brinsmead Cbe, Non-Executive Independent Director

Jez Moulding, Chief Operating Officer

SECTION 7 UDG HEALTHCARE PLC ACTIVITIES

UDG Healthcare PLC, together with its subsidiaries, provides outsourced services to healthcare manufacturers in the distribution, sales and marketing, regulatory, and packaging areas in Ireland, the United Kingdom, the United States, and Continental Europe. The companys Healthcare Supply Chain segment provides delivery services of pharmaceuticals and consumer health products to retail and hospital pharmacies; and contract distribution and other services to pharmaceutical, consumer health, and animal health manufacturers. This segment also sells, distributes, and supports consumable and capital equipment to healthcare providers, and industry and research institutions; and manufactures and distributes specially prepared products to meet specific patient prescription requirements for the retail pharmacy and hospital markets. Its Sales, Marketing, and Medical segment offers contract sales outsourcing, and sales and marketing services, including medical affairs information, patient compliance support, clinical trials recruitment, and sales force effectiveness training services to the pharmaceutical sector; and bespoke event management and logistical services. This segment also provides healthcare communications and consultancy services to pharmaceutical and biotechnology companies, such as medical writing and publication planning, market research and business analysis, marketing and sales training, and consultancy for various stages of the product lifecycle. The companys Packaging and Specialty segment offers outsourced primary and secondary packaging solutions to pharmaceutical manufacturers; and homecare services to the NHS and the pharmaceutical industry, as well as nurse-led homecare services to the healthcare sector. This segment also provides healthcare services in the travel field consisting of sale and distribution of vaccines; and medical information and clinical services. The company was founded in 1948 and is based in Dublin, Ireland.

SECTION 8 RECENT NEWS ON DIRECTORS

8.1 CHANGES IN BOARD OF DIRECTORS AND SENIOR MANAGEMENT

04 May 2018

UDG Healthcare CFO Alan Ralph - to step down

Alan Ralph of UDG Healthcare will step down as CFO. The effective date is May 15, 2018.

04 May 2018

UDG Healthcare will appoint Nigel Clerkin as CFO

UDG Healthcare will appoint Nigel Clerkin as CFO. The appointment takes effect from May 15, 2018.

04 May 2018

UDG Healthcare will appoint Nigel Clerkin as director

UDG Healthcare will appoint Nigel Clerkin as Executive Director. The appointment takes effect from May 15, 2018.

8.2 SHAREHOLDER VALUE ADDED BY DIRECTORS

20 June 2018

Nancy Miller-Rich starts third year as UDG Healthcare Non-Executive Director

Nancy Miller-Rich was appointed Non-Executive Director of UDG Healthcare (L:UDG) two years ago on June 20, 2016. The shares were up from GBP566.4 to GBP845.5 and the total annualized return to shareholders (TRS) since appointment is 24.1%. The present value of GBP1,000 (PV1000) invested on the appointment date is now worth GBP1,541, a gain of GBP493 and dividend reinvested of GBP48.

01 April 2018

Myles Lee starts second year as UDG Healthcare Non-Executive Director

Myles Lee was appointed Non-Executive Director of UDG Healthcare (L:UDG) one year ago on April 01, 2017. The shares were up from GBX693.4 to GBX868.0 and the total annualized return to shareholders (TRS) since appointment is 26.7%. The present value of GBP1,000 (PV1000) invested on the appointment date is now worth GBP1,267, a gain of GBP252 and dividend reinvested of GBP16.

8.3 RECENT REPORTED BUYING

14 August 2018

UDG Healthcare director Myles Lee buys

UDG Healthcare (L:UDG) Non-Executive Director Myles Lee bought 4,000 shares worth GBP30,080 ($US38,363) on August 09. The purchase price was GBP7.52.

14 August 2018

UDG Healthcare chief financial officer and executive director Nigel Clerkin buys

UDG Healthcare (L:UDG) Chief Financial Officer and Executive Director Nigel Clerkin bought 20,000 shares worth GBP148,000 ($US188,755) on August 08. The purchase price was GBP7.40. The shares hit a twenty one-month low on the day.

14 August 2018

UDG Healthcare chief financial officer and executive director Nigel Clerkin buys

UDG Healthcare (L:UDG) Chief Financial Officer and Executive Director Nigel Clerkin bought 20,000 shares worth GBP149,000 ($US190,030) on August 09. The purchase price was GBP7.45.

Source: www.BuySellSignals.com